Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus HN001

What does the research say about Lactobacillus rhamnosus HN001?

3 health outcomes synthesised

Lactobacillus rhamnosus HN001 has been researched across three health outcomes, primarily in pregnant and postpartum women and their children. The strongest evidence area is for reduced anxiety, with 4 studies showing mostly beneficial effects. The most studied dose is 6 × 10^9 colony-forming units daily, often taken from pregnancy through the postpartum period.

Strongest evidence: The most promising area for Lactobacillus rhamnosus HN001 is reduced anxiety, though the overall evidence strength is low. Across 4 studies, 3 reported beneficial effects, with one large 2017 RCT (n=423) finding a moderate effect (OR=0.44, p=0.002) for clinically relevant anxiety in pregnant and postpartum women. Doses typically involved daily supplementation from enrolment until 6 months postpartum if breastfeeding.

Mixed or weaker evidence: For reduced eczema prevalence, evidence is mixed: only 1 of 3 studies reported a large beneficial effect, while 2 found neutral results. The evidence for reducing atopic sensitization is consistently neutral—all 3 studies showed no significant benefit. Both outcomes have low evidence strength and small study bases.

Effective dose patterns: The most common dose across studies is 6 × 10^9 CFU daily, used for both eczema and atopic sensitization research. For anxiety, dosing was typically daily from pregnancy through 6 months postpartum, rather than a fixed CFU number.

Population insights: Research predominantly involves pregnant and postpartum women and their children, including high-risk birth cohorts for allergic conditions. Most studied populations are from clinical trials in these groups, limiting generalizability to other demographics such as men, non-pregnant women, or elderly populations.

Notable caveats: The evidence base is small across all outcomes (3–4 studies each), and conclusions should be considered preliminary. Publication bias is a concern, especially for anxiety, where null-result studies are less likely to be published. Many studies did not reach statistical significance, and effect sizes may be smaller than the predominant direction suggests.

Frequently asked

  • What is Lactobacillus rhamnosus HN001 good for according to research?
    Research suggests Lactobacillus rhamnosus HN001 may help reduce anxiety, with 3 of 4 studies reporting beneficial effects in pregnant and postpartum women. Evidence for reducing eczema prevalence is mixed (1 beneficial study out of 3), while no significant benefit was found for atopic sensitization across 3 studies.
  • What dose of Lactobacillus rhamnosus HN001 is typically used in studies?
    The most common dose studied is 6 × 10^9 CFU (colony-forming units) daily, used in research on eczema and atopic sensitization. For anxiety, dosing typically involved daily supplementation from enrolment until 6 months postpartum if breastfeeding.
  • Who benefits most from Lactobacillus rhamnosus HN001?
    Research has primarily focused on pregnant and postpartum women, with the strongest evidence for anxiety reduction in this group. Some studies also included high-risk birth cohorts for allergic disease, but evidence in other populations (e.g., men, non-pregnant adults, elderly) is lacking.
  • Are there caveats or limitations in the research on Lactobacillus rhamnosus HN001?
    Yes. The evidence base is small across all outcomes (3–4 studies each), and many studies did not reach statistical significance. Publication bias may inflate positive findings, especially for anxiety. All conclusions should be considered preliminary until larger, more robust studies are conducted.
  • Does Lactobacillus rhamnosus HN001 help with eczema?
    The evidence is mixed. Only 1 of 3 studies reported a large beneficial effect on reducing eczema prevalence, while 2 found neutral results. The evidence strength is low, and the beneficial study may reflect differences in population (high-risk cohort) or treatment protocol.
  • Does Lactobacillus rhamnosus HN001 help with atopic sensitization?
    No. Across 3 studies, all reported neutral small-sized effects with no statistically significant findings for reducing atopic sensitization. The evidence strength is low, and the effect appears negligible based on current research.

Most-studied combinations with Lactobacillus rhamnosus HN001

most supplement research is combination research
Also studied with:Bifidobacterium lactis HN019 (3), Lactobacillus rhamnosus MAK79L08R (2), Bifidobacterium longum BB536 (2), Bifidobacterium animalis subsp. lactis HN019 (2)
Back to top